OBJECTIVES: The aim of this study was to estimate the serum activity of paraoxonase 1(PON1) and assess the distribution of PON1 polymorphisms in MS patients in the relapse phase. DESIGN AND METHODS: PON1 and arylesterase (ARE) serum activities were measured in two equal groups (each group 63 cases) of relapsing-remitting MS patients and healthy individuals. RESULTS: Mean values for serum PON1 and ARE activities were 90.3±63.4 and 182.1±128.7IU/L for patients and 99.9±73.3 and 190.8±150.3IU/L for controls. Those values were not statistically significant (p=0.242 and p=0.378), respectively. Comparing genotype distributions and allele frequencies in both groups for PON1 Q192R and PON L55M polymorphisms did not show any statistical difference. CONCLUSION: In a selected group of MS patients in relapsing phase no statistically significant difference in PON1 and ARE activities was detected but the mean values for the serum enzyme activities were lower in MS patients.
OBJECTIVES: The aim of this study was to estimate the serum activity of paraoxonase 1(PON1) and assess the distribution of PON1 polymorphisms in MSpatients in the relapse phase. DESIGN AND METHODS: PON1 and arylesterase (ARE) serum activities were measured in two equal groups (each group 63 cases) of relapsing-remitting MSpatients and healthy individuals. RESULTS: Mean values for serum PON1 and ARE activities were 90.3±63.4 and 182.1±128.7IU/L for patients and 99.9±73.3 and 190.8±150.3IU/L for controls. Those values were not statistically significant (p=0.242 and p=0.378), respectively. Comparing genotype distributions and allele frequencies in both groups for PON1Q192R and PONL55M polymorphisms did not show any statistical difference. CONCLUSION: In a selected group of MSpatients in relapsing phase no statistically significant difference in PON1 and ARE activities was detected but the mean values for the serum enzyme activities were lower in MSpatients.